Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Gregory Camus, PhD

Sr Research Scientist II
Gilead Sciences Inc

Disclosure(s): Gilead Sciences: Employee and shareholder, Stocks/Bonds

Poster(s):

1149 - Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET